212 related articles for article (PubMed ID: 37545523)
1. Modeling the tumor microenvironment of anaplastic thyroid cancer: an orthotopic tumor model in C57BL/6 mice.
Xu Z; Shin HS; Kim YH; Ha SY; Won JK; Kim SJ; Park YJ; Parangi S; Cho SW; Lee KE
Front Immunol; 2023; 14():1187388. PubMed ID: 37545523
[TBL] [Abstract][Full Text] [Related]
2. The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.
Vanden Borre P; McFadden DG; Gunda V; Sadow PM; Varmeh S; Bernasconi M; Jacks T; Parangi S
Thyroid; 2014 Apr; 24(4):705-14. PubMed ID: 24295207
[TBL] [Abstract][Full Text] [Related]
3. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ndishabandi D; Ashry T; McCarthy M; Zhou Z; Amin S; Freeman GJ; Alessandrini A; Parangi S
Br J Cancer; 2018 Nov; 119(10):1223-1232. PubMed ID: 30327563
[TBL] [Abstract][Full Text] [Related]
4. Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer.
Ng TSC; Gunda V; Li R; Prytyskach M; Iwamoto Y; Kohler RH; Parangi S; Weissleder R; Miller MA
Radiology; 2021 Jan; 298(1):123-132. PubMed ID: 33107799
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
[TBL] [Abstract][Full Text] [Related]
6. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
Bao L; Li Y; Hu X; Gong Y; Chen J; Huang P; Tan Z; Ge M; Pan Z
Int Immunopharmacol; 2024 May; 133():112102. PubMed ID: 38652971
[TBL] [Abstract][Full Text] [Related]
7. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
8. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous Murine Model of Anaplastic Thyroid Cancer.
Yan H; Ma Y; Zhou X; He Y; Liu Y; Caulin C; Wang L; Xu H; Luo H
J Vis Exp; 2023 Feb; (192):. PubMed ID: 36804915
[TBL] [Abstract][Full Text] [Related]
10. The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment.
Iesato A; Li S; Sadow PM; Abbasian M; Nazarian A; Lawler J; Nucera C
Thyroid; 2023 Jul; 33(7):835-848. PubMed ID: 37171127
[No Abstract] [Full Text] [Related]
11. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
12. An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice.
Kim S; Park YW; Schiff BA; Doan DD; Yazici Y; Jasser SA; Younes M; Mandal M; Bekele BN; Myers JN
Clin Cancer Res; 2005 Mar; 11(5):1713-21. PubMed ID: 15755992
[TBL] [Abstract][Full Text] [Related]
13. An orthotopic mouse model of anaplastic thyroid carcinoma.
Sewell W; Reeb A; Lin RY
J Vis Exp; 2013 Apr; (74):. PubMed ID: 23628990
[TBL] [Abstract][Full Text] [Related]
14. A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma.
Henderson YC; Mohamed ASR; Maniakas A; Chen Y; Powell RT; Peng S; Cardenas M; Williams MD; Bell D; Zafereo ME; Wang RJ; Scherer SE; Wheeler DA; Cabanillas ME; Hofmann MC; Johnson FM; Stephan CC; Sandulache V; Lai SY
J Clin Endocrinol Metab; 2021 Sep; 106(10):2962-2978. PubMed ID: 34120183
[TBL] [Abstract][Full Text] [Related]
15. Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity.
Maniakas A; Henderson YC; Hei H; Peng S; Chen Y; Jiang Y; Ji S; Cardenas M; Chiu Y; Bell D; Williams MD; Hofmann MC; Scherer SE; Wheeler DA; Busaidy NL; Dadu R; Wang JR; Cabanillas ME; Zafereo M; Johnson FM; Lai SY
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4652-e4665. PubMed ID: 34147031
[TBL] [Abstract][Full Text] [Related]
16. Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer.
Zhou M; Chen Y; Adachi M; Wen X; Erwin B; Mawlawi O; Lai SY; Li C
Biomaterials; 2015 Jul; 57():41-9. PubMed ID: 25913249
[TBL] [Abstract][Full Text] [Related]
17. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.
Nehs MA; Nucera C; Nagarkatti SS; Sadow PM; Morales-Garcia D; Hodin RA; Parangi S
Endocrinology; 2012 Feb; 153(2):985-94. PubMed ID: 22202162
[TBL] [Abstract][Full Text] [Related]
18. Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF.
Antonello ZA; Nucera C
Oncogene; 2014 Nov; 33(47):5397-404. PubMed ID: 24362526
[TBL] [Abstract][Full Text] [Related]
19. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
[TBL] [Abstract][Full Text] [Related]
20. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
Charles RP; Silva J; Iezza G; Phillips WA; McMahon M
Mol Cancer Res; 2014 Jul; 12(7):979-86. PubMed ID: 24770869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
